On May 20, 2021 GeneQuantum Healthcare (Suzhou) reported that it completed a Series C funding to develop its portfolio of site-specific antibody drug conjugate molecules (Press release, GeneQuantum Healthcare, MAY 20, 2021, View Source [SID1234580472]). According to the company, the C round raised several hundreds of millions of RMB, which puts the funding at least in the $50 million range, but the exact amount was not disclosed. GeneQuantum says it has built a differentiated ADC platform that addresses the major problems of ADC drugs: high heterogeneity, narrow therapeutic window and high manufacturing cost. The Series C was led by China Life Private Equity Investment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!